bioRxiv · 10.1101/811182
In vitro Efficacy of Novel Glucan Synthase Inhibitor, Ibrexafungerp (SCY-078), Against Multidrug- and Pan-resistant Candida auris Isolates from the Outbreak in New York
Abstract
We report low MIC50 of Ibrexafungerp (SCY-078) for 102 Candida auris clinical and surveillance isolates from outbreak in New York. The group included C. auris with a variable resistance to antifungal drugs. Five pan-resistant C. auris isolates were susceptible to Ibrexafungerp with low MIC50 range of 0.12-1 {micro}g/ml.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Zhu, Y. C., Barat, S. A., Borroto-Esoda, K., Angulo, D., Chaturvedi, S., Chaturvedi, V.. 2019-10-21. In vitro Efficacy of Novel Glucan Synthase Inhibitor, Ibrexafungerp (SCY-078), Against Multidrug- and Pan-resistant Candida auris Isolates from the Outbreak in New York. https://doi.org/10.1101/811182
Cite the original work for its findings. Save a collection to share your selection of sources.